Market Research Blog

The emergence of the COVID-19 pandemic has changed the delivery of medical care worldwide. The increased pressure due to the growing rate of hospitalization of COVID-19 patients had led to the re-profiling of many hospitals and departments for treating patients with COVID-19. It has mild-moderately affected the virology specimen collection market growth.

The Zika virus and Babesia outbreaks, alongside announcements for their inclusion in virology specimen collection tests, indicate the need for innovation in virology specimen collection technologies, consumables, laboratory testing and instruments. Other countries have also undertaken initiatives to check for new and emerging diseases.

The high cost of technologies and collection kits and usage of flow sensitivity screening are the major factors hampering the growth of the virology specimen collection market.

Some emerging markets such as India, the Middle East, and Africa offer promising virology specimen collection opportunities for players in the industry due to their increasing disposable incomes and improving healthcare infrastructure.

The comparatively high cost of laboratory testing has boosted the increasing use of older and less practical tests, for example, first-generation ELISA. The test has been used in various parts of the world despite its limitation.

The high costs of the virology specimen collection products serve as the critical factor curtailing the growth impetus in the market. There is a crucial requirement to reduce the costs of these products to create demand for virology specimen collection. Otherwise, it is estimated to hinder the virology specimen collection growth even in upcoming years.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-14266

During the diagnostics investigations, different microbiology specimen collection mediums are recommended to stabilize specimens for the detection of viruses and bacteria. Thus, based on these factors, the virology swab sample market is likely to experience innumerable growth avenues in the forthcoming years. It is expected to have a digital future of public health, and there comes a crucial requirement to align the international strategies for evaluation and regulation.

There is high competition among the virology specimen collection market players. Only major companies can afford high-capital investments and the cost of R&D and manufacturing. That prevents new entrants from entering the virology specimen collection market.

Key Takeaways:

• North America is anticipated to be at the forefront of the virology specimen collection market future trends, which can be attributed to the increasing adoption of NAT and technological advancements such as portable diagnostics.
• The bacterial specimen collection segment is projected to lead the virology collection market trend by product type. The high prevalence of tuberculosis (TB) is one of the significant factors contributing to the share of the segment.
• Diagnostic applications are expected to account for a significant portion of the virology specimen collection market size due to a spike in the number of FDA-approved specimen collection kits, transport of viral specimen, and virology swab sample for clinical applications.
• By end use, the hospitals and clinics segment is anticipated to generate the most revenue, owing to an uptick in patients with respiratory viruses and bacterial infections.
• The Asia Pacific market for bacterial and virology sample collection is expected to grow at a rapid pace because of extensive coronavirus testing in Asian countries.
• By technology, the segment of the nasopharyngeal sample is estimated to hold sway on account of rapid detection of transmissible transfusion infections (TTIs) and the rising prevalence of HPV-related cancers and human papillomavirus (HPV).

“Virology specimen collection tests emphasize the need for virology specimen collection technology innovation and adoption, consumables, and instruments. This is projected to drive the demand for the virology specimen collection market further.” opines an FMI analyst.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-14266

Competitive Landscape:A few notable virology specimen collection market players include Puritan Medical Products Co. (UK), Trinity Biotech (Ireland), Dickinson and Company (US), Thermo Fisher Scientific Inc. (US), Vircell S.L. (Spain), Becton, Quidel Corporation (US), Titan Biotech Ltd. (India), Diasorin SA (Italy), Copan Italia S.P.A (Italy), Hardy Diagnostics (US).

These firms and companies are partnering & collaborating with several domestic and international players as a part of the emerging trends in the viral specimen collection market.

• Henkel AG & Co. KGaA of Germany tied up with Origin of California to leverage the latter’s expertise in performing robust mechanical testing at its California facility. Henkel also contributed expertise and technology to developing 3D printed nasopharyngeal swabs for COVID-19 testing and several other recent developments in the virology specimen collection market.
• Under a USD 6.0 million contract with Inflammatix Inc., the US HHS supported the development of the host-response testing technology. The company is working on three diagnostic tests that will provide quick results on whether the infection is bacterial or viral. This enables clinicians to make better-informed, earlier treatment decisions. Such initiatives are also at the heart of the companies’ strategy to expand earlier diagnosis.

Key SegmentsBy Product Type:

• Blood Collection Kits
• Specimen Collection Tubes
• Viral Transport Media
• Swabs

By Sample:

• Blood Samples
• Nasopharyngeal Samples
• Throat Samples
• Nasal Samples
• Cervical Samples
• Oral Samples
• Other Samples

By Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East and Africa (MEA)

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-14266

Interoperability and data sharing will become increasingly pivotal and far-reaching for delivering effective healthcare as populations’ worldwide age and people live longer lives, thereby accelerating the healthcare interoperability solutions market growth.

The adoption of cloud technology related to healthcare services is one of the emerging trends in the healthcare interoperability solutions market and a major driving force.

Electronic health record data is rapidly growing, making it difficult to store large amounts of data on local storage devices without risking losing vital information.

The offline mode makes it difficult to share large amounts of data. As a result, healthcare interoperability software solutions are becoming essential and crucial. They enable easy sharing and storage of big data, which spikes the global healthcare interoperability solutions market size.

Furthermore, the government’s implementation of various healthcare reforms has increased the market’s demand for healthcare interoperability solutions.

On the flip side, raising concerns about the safety and security of patient data is putting a brake on the market. Due to the sheer rise in cyber-attacks worldwide, healthcare companies face a significant challenge in protecting patient information.

The pandemic has had a positive impact on the market for healthcare interoperability solutions, and this is expected to shape the healthcare interoperability solutions market future trends.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-14264

Pre-COVID, healthcare organizations faced challenges with interoperability and ineffective data management, which were exacerbated during the pandemic, and clinicians missed important COVID-19 information due to interoperability issues in healthcare, which resulted in inpatient treatment delays and clinicians’ inability to document patients’ status adequately.

Due to the rapid changes each day of the pandemic, data exchange was ineffective and challenging to coordinate. With new coronavirus variants causing new COVID-19 outbreaks worldwide, data sharing through interoperability becomes even more critical.

On account of the factors mentioned above, the healthcare interoperability solutions market is likely to garner a revenue of about US$ 5.5 Bn by 2026.

Key Takeaways:

• The services segment is expected to account for the largest share in terms of type in the healthcare interoperability solutions market. The recurring cost of services such as software upgrades/updates and maintenance accounts for a large portion of this segment.
• Based on end use, the healthcare providers segment is anticipated to have the highest CAGR in the healthcare interoperability solutions market during the forecast period. The same can be attributed to the rising need to contain rising healthcare costs, patient volume etc.
• Based on level, structural Interoperability possibly sums up the largest share in the healthcare interoperability solutions market due to the widespread adoption of eHealth system interoperability such as e-prescribing.
• Owing to an uptick in demand for data exchange, the on-premise segment is likely to hold the majority of healthcare interoperability solutions market share based on deployment.
• The diagnosis segment is expected to dominate the healthcare interoperability solutions market, given the growing need for adequate information flow for disease diagnosis, allowing healthcare professionals to assess patients’ conditions fully.

“The market for healthcare interoperability solutions is expected to dominate the North American region. Some of the major factors driving the adoption of healthcare interoperability solutions in this region are the growing demand for high-quality healthcare, the implementation of favourable initiatives, effective EHR implementation by healthcare organizations, and healthcare costs have nearly doubled in the last decade, particularly in the United States.

According to the Organization for Economic Co-operation and Development (OECD), public spending on healthcare and long-term care in OECD countries will rise from 6% of GDP in 2018 to nearly 9% by 2030 and 14% by 2060.” affirms an FMI analyst.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-14264

Competitive Landscape in Healthcare Interoperability Solutions Market:The leading companies in the healthcare interoperability solutions market include Koninklijke Philips NV, Interfaceware Inc., Orion Health Group Limited, Infor Inc., Allscripts Healthcare Solutions, Inc., Cerner Corporation, Nextgen Healthcare, Inc., OSP Labs, EPIC Systems Corporation, and Intersystems Corporation.

• Epic Systems is a well-known player in the healthcare interoperability solutions market with registration and scheduling tools, managed care administration and billing applications, and EHR interoperability solutions in healthcare. To promote interoperability, the company launched its novel One Virtual System Worldwide initiative and added new features to its Care Everywhere solution.
• WakeMed Health and Hospitals have invested in Fujifilm’s Synapse VNA and Synapse Accessibility Business viewer to improve health interoperability standards and facilitate real-time coordination, according to FUJIFILM Medical Systems Inc., a significant supplier of clinical imaging and medical informatics software.

Key SegmentsBy Type:

• Software Solutions
• Services

By Level of Interoperability:

• Foundational Interoperability
• Structural Interoperability
• Semantic Interoperability

By End User:

• Healthcare Providers
• Healthcare Payers
• Pharmacies

For in-depth competitive analysis, Buy Now – https://www.futuremarketinsights.com/checkout/14264

The sector is booming due to increased demand for antibiotic-resistant bacterial strains, an ageing population, and a high prevalence of hospital-acquired infection. Additionally, a spike in the proportion of product approvals for sepsis diagnosis is expected to promote demand for sepsis diagnostics.

However, factors such as a lack of experienced specialists for diagnosing sepsis, a lack of knowledge, and the adoption of conventional processes during antibiotic production hamper the sales of sepsis diagnostic.

Owing to the rise in newborn umbilical cord infection occurrences and the number of surgical procedures in these countries, developing markets provide a positive outlook for sepsis diagnostics.

HAIs, also known as nosocomial infections, are a leading source of morbidity and mortality in hospitals around the world. Urinary tract infections, pneumonia, and sepsis are the most frequent hospital-acquired infections (HAIs). In addition, in immunocompromised individuals, aged patients, and people with chronic conditions, HAIs can cause sepsis. Because of the significant rise in HAIs around the world, demand for sepsis diagnostic devices is projected to expand in the future years.

Sepsis is a complex condition to detect, and even a one-minute delay in antibiotic delivery increases the chance of death by 7.6% in septic shock patients with hypertension. As a result of the emerging trends in the sepsis diagnostics market, there is a greater need for quick sepsis detection to avoid antibiotic therapy delays in sepsis patients.

Many sepsis diagnostic companies are growing their product offerings in point-of-care technologies, which can quickly identify sepsis, cut down on diagnosis time, and improve life expectancy after sepsis.

The global sepsis diagnostics market is predicted to reach US$ US$ 770 Mn by 2026.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-14272

Key Takeaways

• Attributed to the presence of a larger consumer population in developing markets such as India and China, the Asia Pacific region of rapid sepsis diagnostics is expected to grow profitably over the forecast period.
• The global sepsis diagnostics market adoption trends indicate North America is likely to generate more than $200 million in revenue by the end of 2026. The sepsis diagnostics companies in the region are growing due to well-established healthcare infrastructure and increased usage of innovative products. Septic poisoning is also one of the leading causes of death in the United States.
• As per the sepsis diagnostics market analysis, microbiology technology is likely to gain traction. Microbiology is expected to generate more than $200 million in income by 2026.
• By product, the sepsis diagnostics market opportunities are divided into blood culture media, assays & reagent kits, devices, and software. The blood culture media segment held the most significant market share during the forecast period. This growth can be ascribed to a rise in blood culture media as a sepsis diagnostics device.

“Sepsis diagnostics device are expensive, limiting the growth of this industry. Additionally, in certain countries, there are no clear guidelines for the treatment of sepsis, and there is a lack of awareness about the repercussions of sepsis if it is not treated effectively.”

Competitive LandscapeOrganizations in the global quality articulation market are consolidating and acquiring systems to gain a competitive advantage and generate significant profits. On the other hand, some players benefit from significant new work systems to gain a competitive advantage in the sepsis diagnostics market statistics.

• Cytovale Inc. and the Biomedical Advanced Research and Development Authority, or BARDA, announced cooperation in April 2020 to increase the use of Cytovale’s Rapid Sepsis Diagnostic System for identifying sepsis in patients with probable respiratory infections, such as COVID-19.
• Immunexpress announced a quick SeptiCyte, a one-hour molecular diagnostic test for sepsis, on Biocartis’ Idylla platform in Europe in October 2020. This is one of the first deeply integrated, immune response-based diagnostics to help clinicians diagnose sepsis and sepsis diagnostics market analysis.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-14272

Key SegmentsBy Product:

• Blood Culture Media
• Assays & Reagents
• Instruments, and Software

By Technology:

• Blood Culture
• Immunoassays
• Molecular Diagnostics
• Flow Cytometry
• Microfluidics
• Biomarkers

By Method:

• Automated Diagnostics
• Conventional Diagnostics

By Pathogen:

• Bacterial Sepsis
• Fungal Sepsis
• Viral Sepsis
• Others

By Test Type:

• Laboratory Tests
• Point-of-Care Tests

By End User:

• Hospitals and Specialty Clinics
• Pathology & Reference Laboratories
• Research Laboratories & Academic Institutes

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-14272

As per veterinary infectious disease diagnostics market study, there is a rise in the number of pets, the rising incidence of zoonotic diseases, the growing adoption for animal-derived food products, the rising demands for pet insurance, the upsurge in animal health expenditure, and the surge in the number of veterinary practitioners and income levels in developed economies which are contributing to the veterinary infectious disease diagnostics market growth.

The overall veterinary infectious disease diagnostics market growth is projected to be hindered by rising pet care expenses. One of the critical challenges restricting veterinarians’ adoption of veterinary infectious disease diagnostics is a dearth of skilled veterinarians and diagnostic infrastructure, particularly in developing countries. Another key hindrance to broader adoption is the expensive cost of modern diagnostic tests.

The COVID-19 pandemic is predicted to have a temporary and moderate effect on the veterinary infectious disease diagnostics market during the forecast period.

On a global scale, there has been an increase in the overall companion animal population and adoption rate. As a result, demand for pet care products and services are predicted to rise as the pet population grows, supporting the growth of related sectors such as veterinary infectious disease diagnostics.

Although the pet insurance industry is growing, the number of animals covered for treatment remains low. As a result, the animal’s owner usually bears the majority of the cost of treatment. Along with the rising cost of pet insurance, the cost of veterinary diagnostic lab treatment is also rising at a rapid pace.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-14276

The majority of veterinary clinics have basic veterinary laboratory testing capabilities.

Veterinary practitioners are under pressure to raise their fees due to the lower pay in this sector compared to other advanced-degree professions such as dentistry and law. In addition, high pet care expenses directly impact the number of visits pet owners make to veterinary lab facilities, limiting the veterinary infectious disease diagnostics market growth.

In the present COVID-19 pandemic, testing has shown that the virus travels more from animal diagnostics to the animal than from human to human or human to animal. Therefore, the demand for PCR panels for virus testing is projected to rise as more pet owners begin testing their animals for the absence of these diseases. This will unlock the veterinary infectious disease diagnostics opportunity for new molecular diagnostics panels to enter the vet lab market.

There is a significant imbalance between veterinary diagnostics demand and supply for veterinary specialists in developing economies such as Brazil, China, and Southeast Asia. The majority of veterinarians operate in private vet labs dedicated to companion animals around the world, resulting in a scarcity of resources for agricultural or food-producing animals.

According to end-users, reference laboratories are likely to dominate veterinary infectious disease diagnostics market growth. The veterinary diagnostics market is being bolstered by an increase in the number of samples for examination and an increase in in-house testing.

The Asia-Pacific area is set to grow lab for vets at a breakneck pace. Veterinary Infectious Disease Diagnostics manufacturers and important players will find attractive prospects in emerging economies like China, India, and South Korea. The region’s market is developing due to rising zoonotic disease occurrences and demand for infectious disease diagnostics.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-14276

Key Takeaways

• The highest veterinary infectious disease diagnostics market is further expected to reach US$ 3.8 Bn by 2032.
• According to AVMA, there were around 26,000 veterinary hospitals & clinics in the U.S. in 2019, and more than 80% of them provided point-of-care testing.
• The consumables, reagents & kits product segment held the largest veterinary infectious disease diagnostics market share of more than 52% in 2021.
• The study finds that Asia-Pacific has the highest veterinary infectious disease diagnostics market growth, which is growing due to the contribution of the following emerging countries such as India, with a CAGR of 11.7%.
• The non-infectious diseases segment held the maximum veterinary infectious disease diagnostics market share of more than 27% of the global revenue in 2021.
• The pathology testing type segment dominated the veterinary infectious disease diagnostics market in 2021 with a share of more than 13% owing to its wide variety of service offerings, such as various lab tests, imaging, and specialized tests.
• The laboratories segment held the largest revenue share of more than 37% in 2021.

Competitive LandscapeThe veterinary infectious disease diagnostics market is competitive, with only a few leading competitors.

Due to their significant regional footprint in many locations, these critical veterinary infectious disease diagnostics manufacturers had a strong market position. Biomerieux S.A., Heska Corporation, IDVet, IDEXX veterinary Laboratories, Inc., and Indical Bioscience are some market leaders.

Recent Developments in the Veterinary Infectious Disease Diagnostics Market

• INDICAL BIOSCIENCE GmbH (Germany) acquired the Svanova product portfolio from Boehringer Ingelheim in April 2021, allowing INDICAL to expand its portfolio by 25 assays for cattle.
• BioChek (Netherlands) expanded to Johannesburg, South Africa, in April 2021.
• Lacuna Diagnostics (US) was acquired by Heska Corporation (US) in January 2021, bolstering the company’s portfolio of point-of-care digital cytology technology and telemedicine services.
• NEOGEN Corporation (US) partnered with Transnetyx Inc. (US) in November 2020, allowing NEOGEN to expand its footprint in the animal genomics and diagnostics sector.

Veterinary Infectious Disease Diagnostics Market Key SegmentsBy Technology:

• Immunodiagnostics
• Molecular Diagnostic
• Others

By Animal Type:

• Companion animal
• Food-producing animals

By End User:

• Reference Laboratories
• Veterinary Hospitals and Clinics
• Point of Care
• Research Institutes & Universities

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-14276